In conclusion, based on a large cohort of cancer patients, our study analyzed mutations in β3‐αC loop in kinase domain of EGFR, ERBB2, MAP2K1, and BRAF, and summarized the drug‐relevant mutations of each gene. This evidence concerns the gene BRAF and cancer.